Dr V Prasada Raju resigns as Managing Director; CFO joins the board

Kmp ResignedManagement Changes View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.7%Reaction day

₹859.70

prior close

₹830.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.4%-9.1% vs market

Pharmaceuticals peers, median of 154sector+0.4%-9.1% vs sector

On the reaction day the stock moved 9.1 pts less than Nifty Smallcap 250 and 9.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-6.9

10m

-5.2

15m

-3.5

30m

-2.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.7+0.4-9.1+0.4-9.1

Next day

-9.6+0.4-10.0+0.2-9.8

-12.7-0.2-12.5-0.2-12.5

-13.5+0.5-14.0+0.9-14.4

-14.2-0.2-14.1+0.0-14.2

-15.9-1.6-14.3-1.3-14.6

-18.0-1.9-16.1-2.0-16.0

15d

-32.3-2.4-30.0-2.8-29.5

-35.4-3.3-32.1-2.9-32.6

-38.0-4.7-33.3-5.6-32.4

-56.1-9.9-46.3-11.2-45.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

On October 28, 2025, Dr V Prasada Raju resigned as Managing Director and Director, effective that day, citing personal priorities. He will remain available to support the handover. CFO Himanshu Agarwal, in post since January 2024, was named an additional director and whole-time director for five years from October 29, pending shareholder approval by postal ballot. The disclosure list of key managerial personnel was also updated.

Likely market impact

Leadership change may weigh on sentiment. The CFO joining the board supports continuity, though the five-year appointment needs shareholder approval.